advertisement
Abstract #107720 Published in IGR 23-4
UGH Syndrome Resolution after IOL Explantation and Concomitant Carlevale IOL Implantation
Kandarakis SA; Petrou P; Katsimpris A; Mitsopoulou D; Chatziralli IP; Kanakis M; Halkiadakis I; Georgalas IOcular Immunology and Inflammation 2023; 0: 1-6
OBJECTIVE: To examine the use of Carlevale IOL placement in patients with UGH, and to evaluate surgical outcomes. DESIGN: In this retrospective study, 28 patients with UGH syndrome that were subjected to IOL explantation and concomitant Carlevale IOL implantation were included in the study. METHODS: Information about VA, IOP, number of glaucoma medication, need for glaucoma surgery, presence of hemorrhage and inflammation were recorded up to 6 months after the procedure. RESULTS: We found a statistically significant increase in mean visual acuity and complete resolution of uveitis in all patients. Mean IOP and the mean number of glaucoma medications were significantly decreased postoperatively, while 14% of patients required additional glaucoma surgery. CONCLUSIONS: IOL explantation and concomitant Carlevale IOL implantation may provide a viable solution for UGH syndrome resolution, increases visual acuity, and decreases the need for glaucoma medication.
First Ophthalmology Department, "G.gennimatas" Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Full article